Document Detail

SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator.
MedLine Citation:
PMID:  1835684     Owner:  NLM     Status:  MEDLINE    
Our studies with the prototypical NEP inhibitor SCH 34826 indicate the potential role of this class of compounds in cardiovascular modulation. The data assembled to date indicate that NEP inhibition elicits significant ANF-like effects in animals and man. The early data generated to date on SCH 34826, when considered with those data generated on other NEP inhibitors, indicate that NEP inhibition may have therapeutic utility in some forms of hypertension and congestive heart failure.
E J Sybertz
Related Documents :
9185974 - Effects of certain vasoactive agents on the long-term pattern of blood pressure, heart ...
2196144 - Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor.
14675884 - Effect of statin therapy added to ace-inhibitors on blood pressure control and endothel...
8961074 - Moexipril versus captopril in patients with mild to moderate hypertension.
3354014 - Treatment of systemic hypertension and intracranial hypertension in cases of brain hemo...
14668594 - Impact of two different types of anal retractor on fecal continence after fistula repai...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical nephrology     Volume:  36     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1992-01-09     Completed Date:  1992-01-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  187-91     Citation Subset:  IM    
Schering Plough Research, Bloomfield, New Jersey 07003.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / pharmacology*
Atrial Natriuretic Factor*
Dioxolanes / pharmacology*
Dipeptides / pharmacology*
Drug Synergism
Heart Failure / drug therapy
Hypertension / drug therapy
Neprilysin / antagonists & inhibitors*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Dioxolanes; 0/Dipeptides; 0/Prodrugs; 105262-04-2/Sch 34826; 83861-02-3/SCH 32615; 85637-73-6/Atrial Natriuretic Factor; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The heart in hypertension.
Next Document:  Atrial natriuretic factor after cardiac surgery with cardiopulmonary bypass in children.